The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy
Summary Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while the PRIMA‐PI was built on rituximab chemotherapy. Our objective was t...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2020-12, Vol.191 (5), p.738-747 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 747 |
|---|---|
| container_issue | 5 |
| container_start_page | 738 |
| container_title | British journal of haematology |
| container_volume | 191 |
| creator | Kimby, Eva Lockmer, Sandra Holte, Harald Hagberg, Hans Wahlin, Björn E. Brown, Peter Østenstad, Bjørn |
| description | Summary
Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while the PRIMA‐PI was built on rituximab chemotherapy. Our objective was to evaluate these two prognostic tools in a cohort of 291 patients with FL treated in two prospective randomised Nordic Lymphoma Group trials with rituximab ± interferon. All patients had symptomatic/progressive disease and were previously untreated. The PRIMA‐PI was prognostic for both time to treatment failure (TTF) and overall survival (OS) (log‐rank P = 0·003 and P |
| doi_str_mv | 10.1111/bjh.16692 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_471284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2466682931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4872-c65500a098888c47f50fc0229128cf63be3c691404b2a847a114f92288854b0f3</originalsourceid><addsrcrecordid>eNp1kc9u1DAQxiMEokvhwAuAJU5IpB07jjc5LuVPi4pAqHC1HK_deEniYMfa7o0zJ56RJ2HabHvrXOwZ_fzNeL4se07hiGIcN5v2iApRswfZghaizBnl9GG2AIBlToFXB9mTGDcAtICSPs4OCsYpMAGL7M9Fa0h0_dg568yaWN91TqdOBdLt-rH1vSJfv519Xv37_XcM_nLwcXKauGFtroiLJEVjU4c5GdXkzDBFsnVTS6wLccI3nRsM0a3pPSY2GEOCm9KV61WDhUZF7Dm1Jqhx9zR7ZFUXzbP9eZh9__D-4uQ0P__y8exkdZ5rXi1ZrkVZAiioKwzNl7YEq4GxmrJKW1E0ptCiphx4w1TFl4pSbmvGkC55A7Y4zPJZN27NmBo5Bpwm7KRXTu5LP_FmJF-iJEf-zb38O_djJX24lClJXoJgDPGXM66Dw10NcvBBSQpVyWRVFgKQeDUTuNBfycRJbnwKA_5ZMi6EqFhdUKRe3-r4GIOxd40pyGvbJdoub2xH9sVeMTW9Wd-Rtz4jcDwDW9eZ3f1K8u2n01nyP7clunc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2466682931</pqid></control><display><type>article</type><title>The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy</title><source>Wiley Free Content</source><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>Wiley Online Library Journals Frontfile Complete</source><source>SWEPUB Freely available online</source><creator>Kimby, Eva ; Lockmer, Sandra ; Holte, Harald ; Hagberg, Hans ; Wahlin, Björn E. ; Brown, Peter ; Østenstad, Bjørn</creator><creatorcontrib>Kimby, Eva ; Lockmer, Sandra ; Holte, Harald ; Hagberg, Hans ; Wahlin, Björn E. ; Brown, Peter ; Østenstad, Bjørn</creatorcontrib><description>Summary
Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while the PRIMA‐PI was built on rituximab chemotherapy. Our objective was to evaluate these two prognostic tools in a cohort of 291 patients with FL treated in two prospective randomised Nordic Lymphoma Group trials with rituximab ± interferon. All patients had symptomatic/progressive disease and were previously untreated. The PRIMA‐PI was prognostic for both time to treatment failure (TTF) and overall survival (OS) (log‐rank P = 0·003 and P < 0·001, respectively). The PRIMA‐PI high‐risk identified a small group of patients with a very short TTF and OS compared to the low‐risk group, with a hazard ratio (HR) of 1·90 (95% confidence interval [CI] 1·30–2·78, P = 0·001) and HR of 3·19 (95% CI 1·75–5·83, P < 0·001), respectively. The FLIPI risk groups were prognostic only for OS (log‐rank P = 0·018). The simplified PRIMA‐PI was valid in our FL cohort with first‐line rituximab‐containing chemo‐free therapy and shows an improved risk stratification compared to the FLIPI, especially in patients aged >60 years. Patients in the PRIMA‐PI high‐risk group should be considered for alternative therapies.</description><identifier>ISSN: 0007-1048</identifier><identifier>ISSN: 1365-2141</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.16692</identifier><identifier>PMID: 32410260</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Age Factors ; Aged ; Aged, 80 and over ; chemo-free regimen ; Chemotherapy ; Clinical trials ; Disease-Free Survival ; Female ; follicular lymphoma ; Hematology ; Humans ; Immunotherapy ; Interferon ; Lymphoma ; Lymphoma, Follicular - drug therapy ; Lymphoma, Follicular - mortality ; Male ; Middle Aged ; Monoclonal antibodies ; prognosis ; Risk Factors ; Risk groups ; Rituximab ; Rituximab - administration & dosage ; Rituximab - adverse effects ; Survival Rate ; Targeted cancer therapy</subject><ispartof>British journal of haematology, 2020-12, Vol.191 (5), p.738-747</ispartof><rights>2020 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4872-c65500a098888c47f50fc0229128cf63be3c691404b2a847a114f92288854b0f3</citedby><cites>FETCH-LOGICAL-c4872-c65500a098888c47f50fc0229128cf63be3c691404b2a847a114f92288854b0f3</cites><orcidid>0000-0001-9799-9428 ; 0000-0003-3078-6131</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.16692$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.16692$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,776,780,881,1411,1427,26544,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32410260$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-450622$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:143682422$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Kimby, Eva</creatorcontrib><creatorcontrib>Lockmer, Sandra</creatorcontrib><creatorcontrib>Holte, Harald</creatorcontrib><creatorcontrib>Hagberg, Hans</creatorcontrib><creatorcontrib>Wahlin, Björn E.</creatorcontrib><creatorcontrib>Brown, Peter</creatorcontrib><creatorcontrib>Østenstad, Bjørn</creatorcontrib><title>The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while the PRIMA‐PI was built on rituximab chemotherapy. Our objective was to evaluate these two prognostic tools in a cohort of 291 patients with FL treated in two prospective randomised Nordic Lymphoma Group trials with rituximab ± interferon. All patients had symptomatic/progressive disease and were previously untreated. The PRIMA‐PI was prognostic for both time to treatment failure (TTF) and overall survival (OS) (log‐rank P = 0·003 and P < 0·001, respectively). The PRIMA‐PI high‐risk identified a small group of patients with a very short TTF and OS compared to the low‐risk group, with a hazard ratio (HR) of 1·90 (95% confidence interval [CI] 1·30–2·78, P = 0·001) and HR of 3·19 (95% CI 1·75–5·83, P < 0·001), respectively. The FLIPI risk groups were prognostic only for OS (log‐rank P = 0·018). The simplified PRIMA‐PI was valid in our FL cohort with first‐line rituximab‐containing chemo‐free therapy and shows an improved risk stratification compared to the FLIPI, especially in patients aged >60 years. Patients in the PRIMA‐PI high‐risk group should be considered for alternative therapies.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>chemo-free regimen</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>follicular lymphoma</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interferon</subject><subject>Lymphoma</subject><subject>Lymphoma, Follicular - drug therapy</subject><subject>Lymphoma, Follicular - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>prognosis</subject><subject>Risk Factors</subject><subject>Risk groups</subject><subject>Rituximab</subject><subject>Rituximab - administration & dosage</subject><subject>Rituximab - adverse effects</subject><subject>Survival Rate</subject><subject>Targeted cancer therapy</subject><issn>0007-1048</issn><issn>1365-2141</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>3HK</sourceid><sourceid>D8T</sourceid><recordid>eNp1kc9u1DAQxiMEokvhwAuAJU5IpB07jjc5LuVPi4pAqHC1HK_deEniYMfa7o0zJ56RJ2HabHvrXOwZ_fzNeL4se07hiGIcN5v2iApRswfZghaizBnl9GG2AIBlToFXB9mTGDcAtICSPs4OCsYpMAGL7M9Fa0h0_dg568yaWN91TqdOBdLt-rH1vSJfv519Xv37_XcM_nLwcXKauGFtroiLJEVjU4c5GdXkzDBFsnVTS6wLccI3nRsM0a3pPSY2GEOCm9KV61WDhUZF7Dm1Jqhx9zR7ZFUXzbP9eZh9__D-4uQ0P__y8exkdZ5rXi1ZrkVZAiioKwzNl7YEq4GxmrJKW1E0ptCiphx4w1TFl4pSbmvGkC55A7Y4zPJZN27NmBo5Bpwm7KRXTu5LP_FmJF-iJEf-zb38O_djJX24lClJXoJgDPGXM66Dw10NcvBBSQpVyWRVFgKQeDUTuNBfycRJbnwKA_5ZMi6EqFhdUKRe3-r4GIOxd40pyGvbJdoub2xH9sVeMTW9Wd-Rtz4jcDwDW9eZ3f1K8u2n01nyP7clunc</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Kimby, Eva</creator><creator>Lockmer, Sandra</creator><creator>Holte, Harald</creator><creator>Hagberg, Hans</creator><creator>Wahlin, Björn E.</creator><creator>Brown, Peter</creator><creator>Østenstad, Bjørn</creator><general>Blackwell Publishing Ltd</general><general>Blackwell Science Ltd</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>3HK</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0001-9799-9428</orcidid><orcidid>https://orcid.org/0000-0003-3078-6131</orcidid></search><sort><creationdate>202012</creationdate><title>The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy</title><author>Kimby, Eva ; Lockmer, Sandra ; Holte, Harald ; Hagberg, Hans ; Wahlin, Björn E. ; Brown, Peter ; Østenstad, Bjørn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4872-c65500a098888c47f50fc0229128cf63be3c691404b2a847a114f92288854b0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>chemo-free regimen</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>follicular lymphoma</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interferon</topic><topic>Lymphoma</topic><topic>Lymphoma, Follicular - drug therapy</topic><topic>Lymphoma, Follicular - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>prognosis</topic><topic>Risk Factors</topic><topic>Risk groups</topic><topic>Rituximab</topic><topic>Rituximab - administration & dosage</topic><topic>Rituximab - adverse effects</topic><topic>Survival Rate</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kimby, Eva</creatorcontrib><creatorcontrib>Lockmer, Sandra</creatorcontrib><creatorcontrib>Holte, Harald</creatorcontrib><creatorcontrib>Hagberg, Hans</creatorcontrib><creatorcontrib>Wahlin, Björn E.</creatorcontrib><creatorcontrib>Brown, Peter</creatorcontrib><creatorcontrib>Østenstad, Bjørn</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>NORA - Norwegian Open Research Archives</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kimby, Eva</au><au>Lockmer, Sandra</au><au>Holte, Harald</au><au>Hagberg, Hans</au><au>Wahlin, Björn E.</au><au>Brown, Peter</au><au>Østenstad, Bjørn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2020-12</date><risdate>2020</risdate><volume>191</volume><issue>5</issue><spage>738</spage><epage>747</epage><pages>738-747</pages><issn>0007-1048</issn><issn>1365-2141</issn><eissn>1365-2141</eissn><abstract>Summary
Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while the PRIMA‐PI was built on rituximab chemotherapy. Our objective was to evaluate these two prognostic tools in a cohort of 291 patients with FL treated in two prospective randomised Nordic Lymphoma Group trials with rituximab ± interferon. All patients had symptomatic/progressive disease and were previously untreated. The PRIMA‐PI was prognostic for both time to treatment failure (TTF) and overall survival (OS) (log‐rank P = 0·003 and P < 0·001, respectively). The PRIMA‐PI high‐risk identified a small group of patients with a very short TTF and OS compared to the low‐risk group, with a hazard ratio (HR) of 1·90 (95% confidence interval [CI] 1·30–2·78, P = 0·001) and HR of 3·19 (95% CI 1·75–5·83, P < 0·001), respectively. The FLIPI risk groups were prognostic only for OS (log‐rank P = 0·018). The simplified PRIMA‐PI was valid in our FL cohort with first‐line rituximab‐containing chemo‐free therapy and shows an improved risk stratification compared to the FLIPI, especially in patients aged >60 years. Patients in the PRIMA‐PI high‐risk group should be considered for alternative therapies.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>32410260</pmid><doi>10.1111/bjh.16692</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-9799-9428</orcidid><orcidid>https://orcid.org/0000-0003-3078-6131</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2020-12, Vol.191 (5), p.738-747 |
| issn | 0007-1048 1365-2141 1365-2141 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_471284 |
| source | Wiley Free Content; MEDLINE; NORA - Norwegian Open Research Archives; Wiley Online Library Journals Frontfile Complete; SWEPUB Freely available online |
| subjects | Adult Age Factors Aged Aged, 80 and over chemo-free regimen Chemotherapy Clinical trials Disease-Free Survival Female follicular lymphoma Hematology Humans Immunotherapy Interferon Lymphoma Lymphoma, Follicular - drug therapy Lymphoma, Follicular - mortality Male Middle Aged Monoclonal antibodies prognosis Risk Factors Risk groups Rituximab Rituximab - administration & dosage Rituximab - adverse effects Survival Rate Targeted cancer therapy |
| title | The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T05%3A09%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20simplified%20follicular%20lymphoma%20PRIMA%E2%80%90prognostic%20index%20is%20useful%20in%20patients%20with%20first%E2%80%90line%20chemo%E2%80%90free%20rituximab%E2%80%90based%20therapy&rft.jtitle=British%20journal%20of%20haematology&rft.au=Kimby,%20Eva&rft.date=2020-12&rft.volume=191&rft.issue=5&rft.spage=738&rft.epage=747&rft.pages=738-747&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.16692&rft_dat=%3Cproquest_swepu%3E2466682931%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2466682931&rft_id=info:pmid/32410260&rfr_iscdi=true |